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Abstract
Nicholas Schifano
INVESTIGATION OF THE ROLE OF HYDRPHOBIC AMINO ACIDS ON THE
STRUCTURE-ACTIVITY RELATIONSHIP IN PONERICIN L1 FROM NEOPONERA
GOELDII
&
EFFECT OF CHARGE AND HYDROPHOBICITY IN ANTIMICROBIAL
POLYMETHACRYLATE POLYMERS
2020-2021
Gregory A. Caputo, Ph.D.
Master of Science in Pharmaceutical Science

Due to the increase prevalence of antimicrobial resistance (AMR) antibiotic
alternatives have been of great interest. Antimicrobial peptides (AMPs) and polymers like
polymethacrylates that mimic AMPs are two non-traditional antimicrobial agents that
have been investigated thoroughly over the years as a potential solution to the AMR
problem. This study will further the understanding of the L1 peptide by investigating the
role hydrophobic amino acids have on the antimicrobial activity. Biophysical and
microbiological techniques were utilized to show that the L1 hydrophobic derivative
showed enhanced binding to anionic lipid bilayers while maintaining low hemolytic
activity. This study also elucidates the effect of charge and hydrophobicity on
polymethacrylate polymers by imploring the same techniques and methods used to
investigate the Ponericin L1 peptide. These results indicate that both charge and
hydrophobicity have an impact on activity and selectivity. As hydrophobicity increased,
so did the hemolytic activity, suggesting a balance between hydrophobicity and charge is
needed to optimize antimicrobial activity as well as selectivity. Overall, the results show
that these AMPs and polymethacrylates have great potential as a platform against AMR.
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Chapter 1
Antimicrobials and a Need for Alternatives

History of Antimicrobials
Antibiotics are a major line of defense against infectious bacteria, a progression
in the development of antibiotics has allowed for significant progress in medical practices
[1]. Alexander Fleming was known for the discovery of penicillin, and the impact it had
on the field of medicine. Although the revolutionary nature of penicillin, it was not until
1943 that penicillin was mass produced and used commercially [2]. This was because the
stability of the compound and the science that was available made it tougher than
expected to purify this compound. Penicillin encompassed Paul Ehrlich’s idea of the
“magic bullet”, which is the idea that a drug selectively targets a disease-causing microbe
and not the host themselves. However, the unexpected problem of the purification almost
led to the extinction to this concept until 1930 when the development of sulfa drugs
became prevalent. A compound that was derived from oil dyes by the name of
sulfamidochrysoidine or commonly referred to as prontosil. This was discovered to have
limited success with its bacteriologic activity in animals but not invitro. This was
resolved in 1935, when it was elucidated that sulfanilamide was the primary active
compound within prontosil. This discovery not only led to a Nobel prize in 1939 but
revived the search for the perfect “magic bullet” [3]. From 1944 to 1972 deaths caused
from bacterial infection had decreased and a new life expectancy had jumped by eight
years. This era is now referred to the golden age of antibiotics [4].
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Traditional Antibiotics
Drug-target interactions are the mechanisms of a drug that occur during the
interaction with the intended target. Four most common antibiotic target mechanisms are
the inhibitions of DNA, RNA, cell wall, and protein syntheses. Quinolones inhibit
chromosomal topology that is essential for the synthesis of DNA, mRNA transcription,
and cell division. Quinolone antimicrobial agents target one of two enzymes more
efficiently depending on the type of bacteria. Topo IV is the target in Gram-positive
bacteria; however DNA gyrases are the target in Gram-negative [5-8]. RNA synthesis is
another quintessential part of every cell. Antibiotics that inhibit this synthesis have a
selectivity to target RNAP or RNA polymerase. This method of action permits a wide
range of activity, specificity of the drug, and high efficacy. Four different classes that
participate in this mechanism are rifamycin, sorangicin, streptolydigin, and myxopronin.
Each class has a different binding site but have the same outcome of disrupting RNA
synthesis [5,9,10]. Antibiotics also can affect the cell wall of a bacterial cell. Cell wall
Biosynthesis Inhibitors (CBIs) are one of the most effective classes of antibiotics that are
available. There are three stages of cell biogenesis that the antibiotics target to cause cell
lysis. In the first stage or the cytoplasmic stage, an antibiotic like Fosfomycin will inhibit
a specific enzyme to starve the bacteria cell. Tunicamycin will target the lipid II
component of a cell, causing cell death from the second stage, the membrane associated
stage. Beta-lactam antibiotics like penicillin are a classical example of an antimicrobial
agent that targets proteins like the lactam binding protein to inhibit the third stage,
extracytoplasmic stage. There are a wide range of activities for CBI’s which lead to lytic
or non-lytic death [11]. Antibiotics also have the capability to inhibit protein synthesis
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and is the broadest of classes of antibiotics. 30s and 50s are two subclasses and refer to
the ribonucleoprotein that organize the initiation phase for protein synthesis. A 30S
inhibitors like aminoglycosides will bind tightly to the 30S subunit that will cause a
misreading in mRNA, or like tetracycline will bind to 30S and prevent addition of amino
acids containing tRNA. Protein synthesis inhibitors of the 50S subclass have a wider
range of activities. These inhibitors can bind to the 50S subunit and inhibits the formation
of peptide bonds. They can also, prevent peptide elongation via binding to the peptide
exit tunnel. Lastly, an integral part of protein synthesis is the formation of the ribosomal
complex that initiates the process of protein synthesis. The 50S subclass can affect the
formation of this complex preventing the process [10,12].
Antibiotics with their wide range of activities do not affect different types of
bacteria the same, some are more effective at killing Gram-positive than Gram-negative.
Gram-negative bacteria have a thinner peptidoglycan layer as well as it resides between
an outer membrane composed of lipopolysaccharides, proteins, and a plasma inner
membrane. Gram-positive bacteria only have a doubly thick peptidoglycan and inner
membrane. Penicillin affects Gram-positive more effectively because of its ability to
disrupt the formation of peptidoglycan. This is because of the composition of cell wall for
Gram-positive versus the composition of Gram-negative. The full exposure of the
peptidoglycan layer leaves it prone to inhibition by penicillin. After this inhibition, the
bacteria cell is fragile and more likely to burst, and because human cells do not contain a
peptidoglycan layer it acts as a “magic bullet” and targets the bacteria specifically
[13,14]. Staphylococcus Aureus is a Gram-positive bacterium that is selectively targeted
by penicillin-like or beta lactam antibiotics.
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Multidrug Resistance
A need for antibiotic alternatives has been strongly recognized since the 1960’s as
the rise of antimicrobial resistance accelerated. Some S. Aureus strains as well as other
bacterial strains have the capability of avoiding imminent death by mediation from a gene
that encodes β-lactamase. Once staphylococci gain exposure to the antibiotic, a gene will
produce the β-lactamase and this enzyme then hydrolyses the β-lactam ring of penicillin.
S. Aureus can also develop resistance to methicillin as well. Methicillin was introduced as
an antibiotic to combat the penicillin resistant strains of staphylococcus. This
antimicrobial agent is a semisynthetic derivative of penicillin. It is in a class of antibiotic
called penicillinase-resistant-penicillin. Penicillinase refers to the enzyme β-lactamase,
and the modifications made to penicillin as an attempt at a solution to this problem. The
strain of staphylococcus that are resistant to methicillin is referred to as MRSA or
Methicillin Resistant Staphylococcus Aureus and the mechanism of defense against the
antibiotic is different. This strain has a gene called mecA which produces penicillinbinding protein 2a (PBP2). This type of protein is responsible for the cross-linking of
peptidoglycan chains. Beta-lactam antibiotics have a poor affinity for binding to PBP2a,
this allows MRSA to survive even at high concentrations [14,15].
Multidrug Resistance (MDR) much like the notorious case of S. aureus is a threat
especially in clinical settings. MDR occurs when the active concentration of a drug is
insufficient in killing the bacteria. This can happen by an accumulation of resistant
plasmids or transposons that encode the resistance of specific antimicrobial agents.
Bacteria can also use energy-dependent efflux pumps to impair the accessibility to the
target [17,18]. In a clinical setting, nosocomial infections are a concern when considering
4

multidrug resistance. Nosocomial infections and MDR for over a century have caused a
burden on the healthcare system, particularly in the intensive care unit (ICU). ICUs have
extensive antimicrobial usage which may promote an emergence of MDR. This coupled
with a patient having a compromised immune system can cause life-threatening situations
[19]. To put this in perspective, the World Health Organization (WHO) reported an
estimated 480 thousand new cases of a Multidrug Resistant Tuberculosis (MDR-TB) that
occurred in 2014. Of the 480 thousand cases, 190 thousand patients died proving MDRTB to pose a threat to control worldwide [20].
Non-typhoidal Salmonella (NTS) are infections caused by all serotypes of
Salmonella enterica with the exception of serovars Typhi and Paratyphi.
Fluoroquinolones drugs are a common choice for treating gastrointestinal infections, for
example NTS infections. However, several studies have shown that NTS have a
decreased susceptibility to this treatment. According to data reported by WHO,
fluoroquinolone resistance in NTS are high in some countries of Africa (30%-35%), of
Eastern Mediterranean region (46%-49%) and in Peru (96%) yet relatively low in the
European region [125]. These problems highlight the need for the development of new
antibiotics, ideally with low potential for resistance.
Although MDR has a large impact and is life threatening or clinical environments,
there are approaches to combat this problem. One of the common approaches is the use of
a combination of antimicrobial agents. This can result in an antibiotic-antibiotic
combination, or an antibiotic-non antibiotic adjuvant molecules to inhibit the B-lactamase
enzyme. This approach can also use two components that will indirectly affect the
bacterial resistance by interfering with the signaling pathway [21]. Macromolecular
5

approaches to eradicate the clinical problems of multidrug resistance are also common.
Synthetic cationic polymers have shown to be useful, one of the most beneficial
characteristics is the ability to reuse polymers without leading to antimicrobial resistance
[22]. A renewed interest in western medicine is the approach of phage therapy. This
approach uses virulent phages that act as parasites preforming lytic cycles on the bacteria.
The mode of action for phages are highly selective, however complex difficulties led to
slow development [23,24]. Metal-based Antimicrobials (MBAs) have also shown to be
an effective approach against AMR. Metal ions are known to be toxic to bacteria, and
transition metals in the D-block have been gaining increasing amount of attention for this
approach. Metals exhibit cytotoxic effects and have seemingly endless complex
formations, and with their electron deficiency metals readily interact with electron-rich
biomolecules [25,26].
History of Antimicrobial Peptides
In 1939 substances under the class of gramicidin were isolated from the bacillus
brevius. This peptide falls under a broad class of antimicrobials called antimicrobial
peptides (AMPs). This AMP has a wide range of antimicrobial activity against Grampositive bacteria. Antimicrobial peptides are used in organisms as a defensive or
offensive mechanism in nature. The difference between a small molecule antibiotic and
an AMP is that an AMP does not rely on an enzymatic mechanism leading to cell death.
A common well accepted mechanism of an AMP targets the envelope of the bacterium
and not proteins or other compounds in the biosynthesis processes [27,28]. Targeting an
integral part of cell structure is a core reason for diminished antimicrobial resistance. It
was also elucidated in a recent investigation that the pharmacodynamics of peptides may
6

also have a part to play [29]. Antimicrobial peptides consist of a sequence of amino acids
that can vary in length and a variation of different amino acid residues. There is a class of
AMPs derived from the secretions of an Indian native frog called Tigerinins. This class of
peptide is one of the smallest sequences, and the smallest represented of the antimicrobial
peptides derived from amphibians. This class of peptide is a short sequence only
containing 11-12 amino acids. Reported in a study done in 2001 it has shown to have
antimicrobial activity against a broad spectrum of bacteria Gram-positive and Gramnegative [30]. Large amino acid sequences are also effective at causing cell death. The
range in length for AMPs can be around 12-50 amino acid residues. A recent review was
done in 2019 comparing different antimicrobial peptides derived from multiple sources.
This review described LL-37, an antimicrobial peptide that has 37 amino acids with two
leucine residues at the N-terminus with traditional antimicrobial activity against Grampositive and Gram-negative bacteria [31].
Isolating antimicrobial peptides from mammals and other organisms is not an
unusual practice in present day. AMPs have been isolated from vertebrates, invertebrates,
plants, and even fungi. In animals AMPs are commonly found in the tissues and organs
that are easily exposed to airborne pathogens, these AMPs act as a first line of defense.
The progression into studies done on host defense peptides (HDPs) started in 1956 when
the first animal host defense peptide was isolated from rabbit leukocytes. This discovery
led to a rapid expansion into the field of antimicrobial peptides. Host defense peptides do
as the name suggests and work directly as an antimicrobial agent, or in immune signaling,
and in some cases work in both fashions. Defensins are an HDP were identified in the
early 1980’s. They were described as cationic, and cysteine rich components residing in
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mammal neutrophil phagocytes. More than 5,000 naturally occurring AMPs were
discovered or synthesized as of 2013 [32,33] and as of 2016 there were over 23,000
AMPs that were discovered [34]. As technology improves, more and more computer
assisted simulations can predict valid peptide structures for antimicrobial activity [35].
Structures and Characteristics of Antimicrobial Peptides
As briefly mentioned, antimicrobial peptides have a range in length typically
between 11-50 amino acids. These sequences are amphipathic and vary in hydrophobic
and cationic amino acids. Due to these characteristics and a positive net charge AMPs
have shown strong activities against bacteria. However, these activities are not limited to
just bacteria and can affect a broad spectrum of organisms. AMPs have shown antiviral
activity [36], antifungal activity [37], perturb protozoan homeostasis in parasites [38],
and can even cause apoptosis in cancer cells [39]. These activities are largely impacted
by the sequence and structure of the antimicrobial peptide.
AMPs can be characterized by their secondary structure. These secondary
structures can be characterized into 4 classifications including: α-helix, β-sheet, loop
structure, and extended structures. Using peptide backbone torsion angles as an
alternative to structural classification will show many different AMP folds [40]. AMPs
that are classified as an α-helical structure are usually amphipathic and cationic. Helical
peptides are the most widely distributed with a level of hydrophobicity and the broadest
spectrum of activity [40]. β-sheet AMPs are characterized by a disulfide bond between at
least two β-strands. These structures are more complicated, and the degrees of β-sheet
can be extremely different between peptide sequences [31,41,42]. Antimicrobial peptide
secondary structures are still considered poorly understood. Most will belong to the four
8

mentioned classifications however, in some cases AMPs can belong to neither of those
classifications [40].
Experimental and theoretical data have shown that most AMPs are either partially
or fully disordered in solution [43-45]. Some AMPs are unstructured in solution.
However, AMPs have the ability to adopt an active secondary structure due to the
hydrophobic and hydrophilic regions being in energetically favorable positions upon
interaction with lipid membranes [46-49]. The formation of an α-helical secondary
structure allows peptide bonds to form hydrogen bonds that will reduce the energetic cost
of transfer. β-sheet induced secondary structures often display discrete cationic and
hydrophobic patches [50]. AMP amphiphilicity is promoted through a steep decrease in
polarity across the membrane and align peptide with the interface gradient. This results in
an interface-partitioned AMP that is orientated with hydrophobic residues directed
toward non-polar region of the bilayer and cationic residues remain close to the charged
and zwitterionic head groups [51]. Due to the poor understanding of the active secondary
structure, the underlying issue that if it is necessary to form this structure for disruption of
bacterial membranes can be viewed as controversial.
Mechanism of Action of Antimicrobial Peptides
Since the discovery of AMPs the mode of action (MOA) has been extensively
studied to be used as a therapeutic agent at full potential. It was previously thought that
the only MOA of AMPs was membrane targeting. However, as understanding MOA
progresses there is increasing evidence that there are several mechanisms [52]. The two
major classes are direct killing or immune modulation. It was briefly mentioned that
AMPs target the envelope however, they can also act like traditional antibiotics and target
9

DNA, RNA synthesis as well as target other specific molecules in the cell [53,54]. The
Multi-hit mechanism upon interactions with a bacterial cell increases the efficiency of
antimicrobial peptides [55].
AMPs adopt an active secondary structure upon interaction with the bacterial cell
membrane. Amphiphilic peptides show their nature upon interaction by folding into
amphipathic α-helices with hydrophobic and hydrophilic faces when adsorbed into lipid
membrane. The initial interactions occur because of electrostatic interactions. The
positively charged AMP interacts with the negatively charged cell membrane and
undergo both adsorption and a confirmational change [56]. AMPs generally show
selectivity with non-hemolytic activity well above their Minimum Inhibitory
Concentration. Magainin 2 a peptide that is derived from the skin of an African claw frog
Xenopus laevis inhibits growth of bacteria at 2-50uM. However, the concentration that
causes hemolysis in human erythrocytes is as high as 1000uM [57,58]. The main factor in
an AMPs ability to selectively target a bacterial cell opposed to a host cell can be
attributed to the cationic property and the composition of membrane for bacteria. Bacteria
cell membranes are rich in phosphatidylglycerol and cardiolipins. The cell walls also
contain anionic lipopolysaccharides making them susceptible to being targeted by AMPs.
Mammalian cells lack this anionic surface charge however, this isn’t the only reason for
the prevention of AMP interaction. Mammalian cells contain a molecule called
cholesterol that has membrane stabilizing characteristics and helps protect attack against
AMPs [59,60].
It is difficult to elucidate a full understanding of the mechanism of action for
AMPs, due to the scale of observation and myriad of pathways that AMPs can take to
10

disrupt a bacterial cell membrane. The four significant models that have been described
are barrel-stave model, toroidal pore model, carpet model and the detergent like model. In
the barrel-stave model peptides are initially oriented parallel to the membrane and
eventually insert themselves perpendicularly which promotes lateral peptide-peptide
interactions. These interactions act in a similar fashion to that of protein ion channels and
for this model an amphipathic peptide structure is crucial. This allows for the
hydrophobic region of the peptide to interact with the membrane and the hydrophilic
regions to form the lumens of the channel. Similarly, the toroidal pore model will insert
itself perpendicularly. The difference between the models is that the arrangement of
hydrophobic and hydrophilic lipid portions is maintained and in a toroidal pore model
they are disrupted. In this model there are alternate surfaces for the head or tail groups to
interact with and adds ion selectivity and a discrete size. Pore formation is not the only
model that can designate a pathway to membrane disruption. In the carpet model the
peptides are adsorbed in a parallel manner to form a “carpet” to cover the surface, which
then leads to unfavorable reactions. The carpet model can produce interactions to disrupt
the membrane with a detergent like effect disintegrating the membrane by forming
micelles. The final collapse that comes from carpet model can be explained by the
detergent-like model or a pore forming model. However, it does not require specific
peptide-peptide interactions, it also does not require the peptide to bury itself into the
hydrophobic core to form a channel, nor does it need the formation of specific peptide
structures [61-65].
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Physiochemical Properties of Antimicrobial Peptides
It is relatively easy to preform modifications to AMP sequences to help modify
activity and target spectrum, as well as aid in stabilization and bioavailability [65,66].
The modifications that can be done physiologically to affect antimicrobial activity and
target specificity are size, net charge, hydrophobicity, amphipathicity, and solubility [67].
Length is an important property and can be crucial to biological activity. Due to an
entropic balance, short peptide sequences are less likely to form regular secondary
structures. Longer sequences can overcome this with energetically favorable facial
properties [68]. Length can also contribute to different 3D structures; however, it also has
the possibility of increasing cytotoxicity. An investigation published in 2006 was done to
elucidate possible effects when increasing chain length. Simple sequence repeats, (RW)n
(where n equals 1,2,3,4, or 5) were used to investigate a possible role of sequence length
by comparing the antimicrobial activity as well as hemolytic activity. The conclusion was
that for this sequence that the optimal length was at n equals 3. As the length increased so
did antimicrobial and hemolytic behaviors. Although results were similar for n = 3,4, or 5
the sequence where n equals 3 is the best choice for efficiency in synthesis [69]. When
designing synthetic AMPs, it is important to consider length in a manner of a cost and
time effective product as well.
The net charge is determined by the summation of ionizable groups in the peptide.
Majority of cationic AMPs (CAMPs) have two unique features one of the being a
positive net charge of at least +2 and the other is an amphipathic character. It is theorized
that the net positive charge is the main cause for the initial interaction due the bacterial
membrane being negatively charged. It has been elucidated from a study that the net
12

charge of an AMP impacts the antimicrobial activity as well as hemolytic activity. A
study was done using an established AMP named L-V13K which is a 26 amino acid that
adopts an α-helical structure in a hydrophobic environment and has a hydrophilic
positively charged lysine residue at the center. The V13K analogs had a net charge that
ranged from -5 to +10. In the study it was observed that lowering the net charge to <+4
rendered the peptide completely inactive, while systematically increasing the charge from
+4 to +8 increased the overall antimicrobial activity while sustaining low hemolytic
activity. However, an increase to +9 and +10 increased antimicrobial activity as well as
unwanted hemolytic activity [70].
Hydrophobic residues that reside within a given AMP have also shown to have
influence over antimicrobial activity and hemolytic activity. Natural AMPs exist with a
broad range of hydrophobicity and charge, commonly natural AMP sequences contain
40-60% hydrophobic residues with a +4 to +6 charge [71]. The cationic nature
contributes to the initial interaction with a negatively charged bacterial cell membrane,
where the hydrophobic components facilitate partitioning into the membrane. Studies
have shown that the hydrophobicity of an AMP has a more complex nature to the
interactions of the cell membrane. For example, data provided by a study done on an
AMP called C18G, when the phenyl alanine residues are replaced by less hydrophobic
leucine residues it drove antimicrobial activity and cytotoxicity. One possible solution
presented from the paper was that the physical orientation of the side chains could also
play an important role in activity as well. The side chains of the hydrophobic residues
could part take in a phenomenon similar to that of cationic side chains that exhibit
“snorkeling” or extending out of the non-polar core of the bilayer. Although this was an
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interesting result of the study, It was also displayed that when the AMP dropped below a
threshold of hydrophobicity will contribute to the reduction of membrane binding,
membrane activity, and antimicrobial activity [72].
Amphipathicity is a result of having both hydrophilic and hydrophobic properties.
This property is important because it ensures that there will be an initial interaction and
activity with selectivity. A study done on cecropins, a family of AMPs that have an
amphipathic N-terminal domain and a hydrophobic C- terminal domain. It was evident
that a substitution of proline residues in the N-terminus significantly reduced
antimicrobial activity, highlighting the importance of an amphipathic α-helix [73,74].
The solubility of an AMP is vital for an initial interaction between the AMP and
the bacterial cell membrane. A lack of solubility can cause inappropriate aggregation
leading to a reduction of the membrane permeabilization effects [75]. Despite this
potential flaw there are some methods to improve solubility of peptides in aqueous
solutions. It is not uncommon to synthesize “hybrid” or “chimeric”, which combines
AMPs or fragments of AMPs to improve properties. Polyethylene glycol moieties
although not extensively explored, are commonly attached to AMPs to increase
solubility. Not only does it increase solubility but improves pharmacokinetics, and halflives [76,77].
Venom-Derived Antimicrobial Peptides
Natural AMPs are diverse which causes difficulties in classification. AMPs can
be classified on activity, structural characteristics, amino acid- rich species, and on source
of the peptide [45]. Venom derived peptides have been a focus of studies and
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modifications and can be a valid example of an AMP being classified by source. Venoms
are complexed mixtures comprised of various enzymes and protein of different sizes that
serve as a defense against microbes. Peptides are a major component in venoms and are
capable but not required to be biologically active [78]. The peptides that do exhibit
biological activity can do so in a myriad of ways. This activity includes membrane
permeabilization, neurotoxins, and even GPCR agonist and antagonists [79]. With a
Small size, acute specificity, significant structural stability these biologically active
peptides are also relatively easy to synthesize making them ideal components for novel
antimicrobial agents [80].
Venoms can be classified into their mode of action and their effect. These include:
Neurotoxins, cardiotoxins, hemotoxin, and cytotoxin. Neurotoxins can inhibit nicotinic
acetylcholine receptors (nAChRs) and interfere with nerve transmission [115] These
toxins can also inhibit ion movement through cellular membrane blocking the movement
of neurons. Cardiotoxins bind to the cells of the heart and block muscle contraction
which generally affect the heart muscle. Hemotoxins cause the destruction of red blood
cells which primarily affect the circulatory system, blood function, and muscle tissue.
Lastly, one of the most researched components of venoms are cytotoxins. Cytotoxins can
affect the cell membrane, interfere with the transportation of substances, or even interfere
with the transduction of signals across the membrane [116]
An increasing amount of studies have been done on membrane active peptides
over the last 20 years. AMPs fall into one of the two classes of membrane peptides, and
the other are cell penetrating peptides (CPP’s) [117]. A well known example of a
membrane active AMP is a peptide derived from honey bee venom called melittin.
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Melittin is a lytic peptide that binds to the membrane surface followed by insertion at
threshold levels of bound peptide. This AMP can bind to membranes in milliseconds and
adopts an amphipathic α-helical structure oriented either parallel or perpendicular to the
plane of the membrane [118]. As the membrane active peptide melittin gained interest it
has been shown to have anticancer activity [119], antifungal activities [120], antiviral
[121], and not only antibacterial but in some cases specifically target drug resistive forms
[122]. CPP’s are short sequence peptides with a positive charge and facilitate penetration
into the cell across the membrane [123]. CPPs like transportan, a chimeric peptide
derived from wasp venom, can act as a cargo carrier as a potential drug delivery system
[124].
Venoms like snake or spider venom are notorious for being toxic and deadly.
However, the safety and pharmacodynamics are not the only issues with venom peptides.
Peptides derived from venoms need to be sufficiently stable to avoid degradation, and
these peptides go through Post Translational Modifications (PTMs) to achieve this
stability. PTMs that are common are amidation (C-terminal), γ-carboxylation (Glu),
hydroxylation (Pro), sulfation (Tyr), bromination (Trp), glycosylation (Thr),
pyroglutamation, N-C-cyclization, and isomerization from into D-amino acids [80].
These modifications enhance peptide properties however for possible therapeutic
applications may not be enough or optimal. Optimizing venom peptides as therapeutics
comes with a list of issues including formulation, cost of production, stability, selectivity,
and MOA.
One of the key weaknesses of venom peptides as potential therapeutic agents is
their low bioavailability which can be attributed to their hydrophilic nature and even their
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small size (10-50 amino acids) [81]. This weakness results in an unfavorable mode of
administering the peptide, which is a site of injection. A previously discussed technique
such as the development of chimeric peptides is often utilized as a possible method to
overcome this issue but is not the only method. Another common method is to use Nalkylation of amino acids, typically N-Methylation is used to improve pharmacokinetics.
Studies were done by N-methylating the cyclic peptide somatosatin. These studies
elucidated that N-methylating at certain points of the peptide it increases the
bioavailability by 10% [82]. Despite these issues that need to be addressed in further
investigations, Venom-derived peptides hold valuable potential for being a model or a
therapeutic agent.
Background on Antimicrobial Polymers
AMPs may be ancient weapons, evolving for millions of years and attacking
bacterial membranes for quite some time, but they are not the only effective defense.
Methacrylate random copolymers that can be classified as an AMP-mimetic polymers
can inhibit the growth of Methicillen-resistant S. aureus (MRSA) and Vancomycinresistant S. aureus (VRSA). Synthetic polymers can be used as an advantageous
antibiotic that mimics an AMPs cationic amphiphilic structure while having diverse
compositions, shapes, and architecture [83]. Due to this feature, polymers can be
relatively easily synthesized to mimic AMPs and gain more insight into peptide SAR.
Polymers have a myriad of advantages over peptides that include inexpensive to
manufacture, easier to produce and alter chemically, and are more amendable in the
integration of drug delivery systems [84]. These strengths and advantages may allow for
the use of polymers to overcome the chemical limitations like bioavailability and oral
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availability that prevent the use of AMPs in clinical settings. Many classes of AMP
mimicking polymers exist already such as polynorbornenes, polycarbonates,
polyalanines, and polymethacrylates. Also, these synthetic polymers can be chemically
altered via facile route and obtain a broader range of chemical structures [85]. The ability
to alter and manipulate to optimize activities is a favorable characteristic of both
polymers and AMPs. Structure Activity Relationship (SAR) studies are relatively easy to
preform to optimize these potential therapeutic agents.
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Chapter 2
Investigation of the Role of Hydrphobic Amino Acids on The Structure-Activity
Relationship in Ponericin L1 from Neoponera Goeldii

Background to Ponericins
Neoponera, a ponerine ant genus is comprised of 57 species of ant composed of
very diverse morphology and behavior. This diverse genus ranges from southern Texas
and northern Mexico to southern Brazil and northern Argentina. Within the ponerine ant
genus, the Neoponera can be considered a cryptic species complex, this is defined as two
or more species being classified as a single nominal species due to being superficially
morphologically indistinguishable. This Includes sympatric species and species with a
wide distribution [86,87]. A predatory ant in the subfamily Ponerinae, called Neoponera
Goeldii (previously misclassified as Pachycondyla Goeldii) has been previously studied
for the antimicrobial activities the peptides that reside in the venom exude [88].
The AMPs that are isolated from the venom of this ant are called Ponericins.
There are fifteen novel peptides that have been extracted that display antibacterial and
insecticidal activities. Of the fifteen peptides all contain cationic, amphiphilic sequences.
Only twelve of the peptides contain a Trp residue in the N-terminal region. There are
three classifications that a ponericin peptide can belong too: G, W, or L. Each class
shares high sequence relationships with different known existing AMPs; Ponericins
belonging to the G classification show similarities with cecropin-like peptides, W with
gaegurins and melittin, and finally L sharing similarities with the natural polycationic
peptides dermaseptins [88].
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The G family has seven of the fifteen novel peptides and has more than half of its
sequence in common with cecropins. Cecropins have activity against Gram-negative and
Gram-positive bacteria cells. These AMPs can also inhibit the uptake of proline, as well
as cause leaky membranes. Ponericins in the W family make up another large portion of
the fifteen novel peptides. This family has spectrum of activity against yeast, bacteria but
also show hemolytic activity. In most sequences for both G and W families there is a
proline residue near the middle of the sequence (11/13). In cell membranes ponericins
naturally adopt α- helix structure [89].
The L family is the smallest and the most poorly understood of the ponericins.
This family consist of two peptide sequences (L1 and L2) each with similarities to
peptides derived from amphibians called dermaseptins. These peptides have had little
recognition, only two papers report the activities and characteristics one of which being
the original report by Orivel et al.. This reported only on the L2 peptide, which elucidated
that ponericin L2 had a broad-spectrum of activity with no hemolytic activity. Ponericin
L1 was reported in a recent study and had shown that this peptide adopts an α-helical
confirmation, has enhanced binding to lipid vesicles with anionic lipids and little to no
hemolytic activity. This study also had shown SARs that displayed the significance that
net charge and group identity had on antimicrobial activity [90]. Ponericin L1 and L2
have identical sequences except for a single amino acid at position 9, where L1 contains a
Met and L2 has an Ile. Although the recent study elucidated information on ponericin L1,
there still is a general lack of understanding when it comes to the L-family of ponericins.
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Figure 1
Peptide Sequences and Helical Wheel Diagrams

Peptide sequences, nomenclature, and properties
Name

Sequence

Net Charge M.W calculated

M.W Found

L1
L1V
L1I
L1L
L1A
L1F

LLKELWTKMKGAGKAVLGKIKGLL
VVKEVWTKMKGAGKAVVGKVKGVV
IIKEIWTKMKGAGKAIIGKIKGII
LLKELWTKMKGAGKALLGKLKGLL
AAKEAWTKMKGAGKAAAGKAKGAA
FFKEFWTKMKGAGKAFFGKFKGFF

5+

2596

2595.4

5+

2498

2497.4

5+

2610

2608.6

5+

2610

2609.2

5+

2274

2273.5

5+

2883

2881.2

Note. Helical wheel diagram of L1, L1V, L1I, L1L, L1A, and L1F. Cationic residues are
shown in blue, anionic in red, hydrophobic in green, polar uncharged in yellow, and
aromatic are in purple. Peptide sequences and relevant properties are shown below the
helical wheel. Helical wheel representations were made using MPEx [91].
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Materials and Methods
Peptide Preparation
Peptide variants L1A and L1F were synthesized using standard FMOC-chemistry
in-house. The parent peptide L1 along with L1-V, L1-I, and L1-L were purchased from
Synthetic Proteomics (Carlsbad, California). Using a Zorbax C3 column, all peptides
were purified via RP-HPLC eluted by a linear gradient of water to acetonitrile (both
supplemented with 0.1% TFA). Peptide identity was confirmed using MALDI-TOF mass
spectrometry. HPLC fractions containing the peptide were collected, pooled, lyophilized,
and stored a at -20 C. Peptides were dissolved in H2O:ethanol 3:1 prior to use. Each
peptide stock was made to a final concentration of 150 -200 μM then stored at 4 C.
Lipid Preparation
Lipids

1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC; PC)1,2-dioleoyl-sn-

glycero-3-phospho-(10-rac-glycerol) (DOPG; PG), and 1-palmitoyl-2-oleoyl-sn-glycero3-phosphoethanolamine (POPE; PE) were purchased from Avanti Polar Lipids
(Alabaster, Alabama), and stored as stocks in chloroform at −20 C. Lipids were prepared
as 100% DOPC, 3:1 DOPC:Cholesterol (PC:Chol), 3:1 DOPC:DOPG (PC:PG), or 3:1
POPE:DOPG (PE:PG). Isopropyl β-D-1-thiogalactopyranoside (IPTG) (Chem-Impex
Int'l INC.), ortho-nitrophenyl-β-galactoside (ONPG) (Research Products International
Co.), nitrocefin (Biovision, Milpitas, California). All other chemicals and reagents were
from Thermo Fisher Scientific (Waltham,Massachusetts), VWR (Radnor, Pennsylvania),
or Sigma-Aldrich (St. Louis, Missouri).
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To form small unilamellar vesicles (SUVs) sonication or ethanol dilution methods
were implemented [92]. In all cases, lipid vesicle preparation was the same. Depending
on the lipid composition, appropriate volumes of lipids in chloroform were mixed in a
glass tube and then allowed to dry under N2 gas for 15 minutes. The lipid films were then
placed in a vacuum desiccator and allowed to dry further under a vacuum for 1 hour. For
vesicles formed through ethanol dilution methods, 10 μL of pure ethanol was added to the
film, and then vortex until the dissipation of the film. While continuing to vortex, the
appropriate amount of PBS was added. For vesicles formed using the method of
sonication, PBS was added directly to the tube while being vortexed to create
multilamellar vesicles (MLVs). The MLV suspension was covered with parafilm and
then placed in a high-powered bath sonicator (Avanti Lipids) and subjected to sonication
for 20 minutes to create SUVs.
Fluorescence Spectroscopy
All fluorescence spectroscopy experiments were performed using a JY-Horiba
Fluoromax4 instrument. Excitation and emission slit widths were kept consistent at 2.5
nm. Semi-micro quartz cuvettes were utilized for each experiment. The following
formula was used to calculate a spectral barycenter for each experiment:

1

𝐵=

∑𝜆 ∗ 𝑖
∑𝑖
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where B is the barycenter, 𝜆 is the wavelength, and 𝑖 is the intensity at the specified
wavelength. An entire emission spectrum from 300-400 was used the carry out the
calculation of barycenter.
Binding Experiments
Lipid binding protocols from previous experiments were used as a basis for the
following reported data. Peptide samples were prepared at final concentration of 2μM in
PBS buffer (150 mM NaCl, 50 mM Na2HPO4, pH 7.0) and titrated with lipid vesicle
stock (usually [1.0] mM total lipid). The standard for all binding assays is λex = 280 nm
and λem = 300 to 400 nm. A sample containing only PBS and no peptide was used as a
background to correct spectra after each addition of vesicles.
Red-Edge Excitation Spectroscopy
Red edge excitation shift (REES) experiments utilized excitation at 6 different
wavelengths (λex = 280, 290, 295, 300, 305, and 307 nm) and the same emission range of
310 to 410 nm. Samples were similarly prepared as above. A blank only containing PBS
buffer was used as background to correct the spectra after each addition.
TCE Quenching
Trichloroethanol (TCE) quenching was monitored by titration of samples with 10
μL aliquots of 10M TCE (Alfa Aesar, Haverhill, Massachusetts) into peptide samples
prepared as described above. After each addition of TCE, Trp fluorescence intensity was
measured using λex = 280 nm and λem = 340. Corrections to the emission intensity were
made for background subtraction and dilutions. The slope of the linear best fit equation to
the data (eqn 2) was used as the Stern-Volmer quenching constant (Ksv).
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2

𝐹0
= 1 + 𝐾𝑠𝑣[𝑄]
𝐹

where F0 is the fluorescence intensity in the absence of quencher, and F is the
fluorescence intensity in the presence of a given concentration of quencher [Q].
Acrylamide Quenching
Acrylamide quenching was monitored by titration of samples with 10 μL aliquots
of 4M acrylamide titrated into peptide samples prepared as described above. These
samples contained either [0] or [0.25] mM total lipid. After each addition of acrylamide,
Trp fluorescence intensity was measured using λex = 295 nm and λem = 340. Corrections
to the emission intensity were made for background subtraction, dilutions, and inner filter
effects in the excitation path as described previously. The same method to calculate Ksv
was used as above.
Circular Dichroism Spectroscopy
Circular

Dichroism

(CD)

spectra

were

collected

via

Jasco

J-810

spectropolarimeter. CD experiments with samples containing SUVs with 200 μM total
lipid and 3 μM peptide in 0.1 x PBS buffer. Each measurement was an average of at least
64 scans and was corrected by subtracting background spectra that did not contain
peptide.
Minimal Inhibitory Concentration(MIC)/Minimal Bactericidal Concentration(MBC)
Six different strains of bacteria were streaked on LB-Miller agar plates from a
frozen glycerol stock derived from the original samples shipped from CGSC (Coli
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Genetic Stock Center, Yale University) or ATCC (American Type Culture Collection)
(Escherichia coli D31 CGSC 5165 , Staphylococcus aureus ATCC 35556. Pseudomonas
aeruginosa PA-01 ATCC 47085, Acinetobacter baumanni ATCC 19606). For each of the
strains a liquid overnight culture was prepared using a single colony into fresh LB broth
and placed in a shaking incubator for ~ 18 hours at 37 C at 225 rpm. After the incubation
period, a 1:200 dilution was made in fresh LB broth and then used for experimentation.
Minimal Inhibitory Concentration (MIC) determinations were performed using mid-log
phase bacteria diluted to 5 x 105 CFU/mL. Next, 90 μL of this diluted culture was then
pipetted into a sterile 96-well plate that contains serially diluted aliquots of the peptide
variants to consist of a total volume of 100 μL. This plate was then incubated for 18
hours at 37 C. Bacterial growth was determined by taking an OD600 measurement using a
Spectramax M5 multimode plate reader post incubation. Minimal Bactericidal
Concentration (MBC) was preformed by taking 1μL of the culture from the MIC plate
and then pipetting it on to a fresh LB agar plate. After plating this culture, the plate was
then incubated overnight at 37 C. MBC was determined by the growth or the lack of
growth from each well on the agar plate.
Bacterial Inner Membrane Permeabilization Assay
A single colony of E.coli D31 was inoculated into LB broth and placed in a
shaking incubator and set to 225 rpm at 37 C for ~ 18 hours. A 1:250 dilution was made
using the overnight culture into fresh LB broth. To induce the expression the expression
of β-galactocidase, A final concentration of 100mM of IPTG was introduced. This
dilution plus the IPTG was placed back into the shaking incubator for about 2 hours until
an OD600 of 0.2-0.4 was achieved.
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A 96 well plate was prepared with the following solutions in order: 10 μL of each
peptide variant 2-fold serially diluted down the plate with the exception of the final row
(used as a negative control 10 μL of 0.01% acetic acid), 56 μL Z-buffer (60mM
Na2HPO4, 40mM NaH2PO4, 10mM KCl, 1mM MgSO4, 50mM β-mercaptoethanol pH 7),
19 μL of the E.coli culture, and 15 μL of 4 mg/ml ONPG that was prepared in Z-buffer
added immediately before the assay began. Absorbance measurements were taken at 420
nm every 5 minutes for a total run time of 90 minutes. The detergent
cetyltrimethylammonium bromide (CTAB) was used as a positive control. The data
presented is an average of three replicates.
Bacterial Outer Membrane Permeabilization Assay
A single colony of E.coli D31 was taken from an LB agar plate and inoculated
into fresh LB broth with 100 μg/mL ampicillin (LB-Amp), then place in a shaking
incubator at 37 C (225 rpm) for ~ 18 hours. After the incubation period 100 μL was taken
from the culture and diluted with 25 mL of fresh LB-Amp. The dilution was further
incubated in the same conditions until an OD600 of 0.2 to 0.4 was obtained. Once the
specified OD600 was reached the culture was then centrifuged at 2500 rpm for 15 minutes
in a tabletop clinical centrifuge. The supernatant was discarded and then an equal amount
of PBS (100 mM NaH2PO4, 200 mM NaCl, pH7) was used to resuspend the pellet.
Experimental samples were prepared in a 96-well plate in the order as follows: 10
μL of the six peptide variants that were serially diluted starting a concentration of 15 μM
with the exception of the last row (used as a negative control 10 μL of 0.01% acetic acid).
80 μL of the resuspended bacteria culture, and 10 μL of 50 μg/mL nitrocefin in PBS. The
absorbance was recorded at 486 nm in 5-minute intervals for a total run time of 90
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minutes immediately following the addition of nitrocefin. The antimicrobial agent
polymyxin B was used as a positive control. The values presented are the average of three
replicates.
Hemolysis
Hemolysis on Sheep red blood cells (RBCs) was used to quantify the
destabilization of membranes by leakage of hemoglobin. Sheep blood was obtained
through Hemostat Laboratories and stored at 2 – 8 C. A 7 mL aliquot of whole sheep
blood was mixed with 7 mL of sterile PBS at pH 7.4. The solution was sedimented via
centrifugation for 7 minutes at 2500 rpm. Supernatant was removed and the pellet was
resuspended to the original volume of 14 mL. This was repeated three times and the final
pellet was resuspended to 14 with PBS. Next, 90 μl of the cell suspension was pipetted
into all wells of a conical bottom 96-well plate. 10 μL of serially diluted peptide variant
or the detergent TX-100 (positive control) were added to the wells prior to addition of the
RBC’s. The plate was covered and left in a shaking incubator at 37 C at 150 rpm for 1
hour. Post incubation the plate was then centrifuged for 10 minutes at 200 rpm at 4 C. 6
μL of the supernatant was added to 94 μl of fresh PBS in a flat bottom plate. The
absorbance of the plate was taken at 415 nm using a Spectramax M5 multimode plate
reader. By using the absorbance of each well compared to the wells without additive and
those with Triton-X 100 a percentage of hemolysis was calculated. The data presented are
the average of three replicates.
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Results
Peptides
All peptides in this study were synthesized via solid-phase peptide synthesis
approaches and purified by reversed-phase HPLC. The sequences used in this study and
relevant physio-chemical properties are shown in Figure 1A. As the L1 peptide has
previously been shown to adopt an α-helical conformation when bound to lipid bilayers, a
helical wheel diagram of the parent L1 sequence is shown in Figure 1B.
Antimicrobial Activity
The ability of L1 and the hydrophobic variants to act as antimicrobials was
investigated using the Minimal Inhibitory Concentration (MIC) and Minimal Bactericidal
Concentration assays as previously described [96]. The MIC is determined as the lowest
concentration of peptide required to inhibit bacterial growth in solution, while the MBC
is the lowest concentration required to act in a bactericidal mechanism (as opposed to
bacteriostatic) and is determined by plating MIC cultures on antimicrobial-free media.
Peptides were screened against E. coli, S. aureus, A. baumanii, P. aeruginosa, B. subtilis,
and K. peunomiae. The results are shown in Table 1.
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Table 1
Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration
(MBC)

L1
L1V
L1I
L1L
L1A
L1F

S. aureus
MIC
MBC
7.50
15
>15
>15
15
15
1.875
3.75
>15
>15
0.938
1.875

E. coli
MIC
MBC
0.94
0.94
>15
>15
0.469
3.75
0.469 0.938
>15
>15
0.938
>15

A. baumanii
MIC
MBC
1.875
3.75
>15
>15
1.875 1.875
0.938 0.938
>15
>15
0.469 0.938

P. aeruginosa
MIC
MBC
>15
>15
>15
>15
>15
>15
15
>15
>15
>15
7.5
>15

B. subtilis
MIC
MBC
0.469 0.938
>15
>15
0.469 0.469
0.469 0.938
>15
>15
1.875 1.875

K. pneuomiae
MIC
MBC
3.75
>15
>15
>15
7.5
7.5
3.75
>15
>15
>15
1.875
7.5

Solution Aggregation Properties
Considering that the first step in the mechanism of action of many AMPs is the
binding to the bacterial cell surface, any aggregation or oligomerization of peptides can
impact the binding equilibrium. If amino acid substitutions promote the aggregated state,
this will then reduce the amount of free peptide available to bind the bacteria and exert
antimicrobial activity.

This is especially relevant in reference to hydrophobic

substitutions as hydrophobicity of a peptide is a significant driver of peptide aggregation
in solution [93-95].
Aggregation of peptides was assessed utilizing the intrinsic fluorescence properties of
the Trp residue in the L1 sequence. Since L1 contains a single Trp, this residue can serve
as a reporter for a variety of peptide characteristics, most notably the environment that
the Trp, and thus the peptide, is sampling. Differences in the side chain motion/dynamics
of the Trp residue and the local environment around the Trp can be observed by
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monitoring the red-edge excitation shifts (REES). This approach monitors shifts in the
emission spectrum as a function of varying the excitation wavelength which is directly
influenced by the mobility and solvent accessibility of the Trp side chain [96]. When a
Trp is exposed to the aqueous milieu and is free to sample rotational conformations, no
REES is exhibited, while if the Trp is constrained or shielded from bulk water REES is
observed as the excitation wavelength is increased. The REES results are shown in
Figure 2A. Notably, all peptides exhibited some degree of REES, with L1V exhibiting
the strongest REES of ~10 nm. Conversely, the L1F peptide exhibited the least REES,
only ~2 nm.
The environment of the L1 Trp residue was further probed using fluorescence
quenching by trichloroethanol (TCE) which selectively exerts quenching on Trp residues
which are shielded from the aqueous milieu, such as at the interior of a peptide aggregate.
The results are shown in Figure 2B, with the Ksv values for the quenching shown in table
2. The majority of the peptides showed similar extent of quenching by TCE except the
L1A variant. The Trp quenching in this peptide sample was markedly lower than the
others. However, considering the reduced overall hydrophobicity of this peptide and thus
higher aqueous solubility, decreased TCE quenching is not surprising. Importantly, the
L1V showed the most quenching, consistent with the REES results.
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Figure 2
Peptide Solution Assays

Note. (A) Red Edge Excitation shift (REES) and (B) Trichloroethanol (TCE) quenching.
The inset column in panel A represents the total shift (nm) for each peptide. In both
panels L1V is shown in Light blue, L1I orange, L1L grey, L1A yellow, and L1F black.
Peptide concentration was 2µM in all samples. All data are averages of three replicates
and SD is represented by error bars.
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Table 2
TCE Quenching

Sequence
L1V
L1I
L1L
L1A
L1F

Ksv[M-1]
9.47
7.59
7.39
4.01
8.08

±
±
±
±
±

1.3
4.9
3.5
0.91
5

Peptide-Lipid Interactions
Considering that the first step in the mechanism of action of many AMPs is the
binding to the bacterial cell surface, binding to model lipid vesicles was performed.
These experiments exploited the inherent environmental sensitivity of Trp as a reporter
for binding to bilayers. In aqueous solution, the Trp fluorescence exhibits a red shifted
emission barycenter, while when bound to bilayers and thus in a more non-polar
environment the Trp emission blue-shifts to lower wavelengths [97,98]. The impact of
lipid composition on binding to model vesicles was investigated using a simple vesicle
titration experiment in which Trp fluorescence was measured after addition of lipid
vesicles. The change in the emission barycenter compared to that in absence of vesicles
was plotted as a function of total lipid concentration (Figure 3). Lipid composition of
vesicles was either 100% DOPC, 3:1 DOPC:DOPG, 3:1 POPE:DOPG, or 7:3
DOPC:Cholesterol. The results show varied behavior that is both peptide and lipid
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composition dependent. The L1L and L1I variants show significantly larger shifts in Trp
emission barycenter when binding PG-containing bilayers, indicating that electrostatic
forces are a strong driver in the bilayer association of these peptides. In contrast, L1F,
L1V, and L1A showed no significant preference for anionic vs. zwitterionic bilayers.
However, only the L1F showed significant shifts in barycenter with the addition of lipid
while L1A and L1V did not. The L1F results indicate that binding in this case is driven
more strongly by hydrophobic interactions independent of the electrostatic contribution.
The L1A and L1V results indicate little interaction with the bilayer, or perhaps only very
shallow interactions with the surface of the bilayer which does not result in a significant
environmental change around the Trp.
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Figure 3
Binding to Lipid Vesicles

Note. Peptide binding was assayed using TRP fluorescence by titrating SUVs into a
peptide containing sample with a final concentration of 2 μM. After each addition the
spectral barycenter was calculated and then a Δ barycenter was calculated by taking the
difference between the initial barycenter and that of each addition. Peptide variants that
were assayed were (A) L1V, (B) L1I, (C) L1L, (D) L1A, (E) L1F. In all panels Blue
represents PC, Orange 3:1 PC:PG, Grey 3:1 PE:PG, and Yellow 3:1 PC:Chol. All data
are averages of 3 replicates and SD is represented by error bars.
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Figure 4
Normalized Trp Emission Spectra

Note. Normalized Trp emission spectra for L1V (A), L1I (B), L1L (C), L1A (D), and L1F
(E) peptides before (red) and after (blue) interacting with lipid vesicles. Data are
representative spectra after subtraction of a background spectrum. All shifts
representative of samples containing 0 µM and 350 µM lipide (PC:PG).
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In order to gain more insight into the bilayer interactions, fluorescence quenching
approaches were utilized.

The peptides were exposed to the aqueous quencher

acrylamide in solution or when bound to vesicles. Acrylamide is known to strongly
quench Trp fluorescence in aqueous environments but does not exert the quenching effect
if the Trp is buried in the non-polar core of the bilayer [99]. Thus, peptide Trp exposure
to the aqueous milieu can be gauged by the extent of quenching by acrylamide. Sternvolmer quenching plots were created to analyze the data and Ksv (slopes of a linear fit to
the data) are shown in Table 2. The trends in this data are consistent with the barycenter
shift data in Figure 3. In the case of L1L and L1I, there was a significant reduction in
quenching between the solution (free) state of the peptide and when bound to anionic
vesicles, but a much smaller reduction if any when interacting with zwitterionic vesicles.
This is consistent with a more deeply buried Trp in anionic bilayers. The L1V and L1A
exhibited differential behavior in this experiment with L1V showing a reduction in
quenching with vesicles, indicating some interaction while the L1A did not exhibit
significant reductions indicating that the Trp is significantly exposed under all conditions.
Importantly, the L1F was the only peptide to exhibit extensive reductions in quenching
when bound to PC:Chol vesicles, consistent with the strong binding to both anionic and
zwitterionic vesicles.
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Table 3
Fluorescence Quenching

Note. Abbreviations: DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine; DOPG, 1,2dioleoyl-sn-glycero-3-phospho-(1’-rac-glycerol). Data are averages of 3 replicates with
SD.
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Figure 5
Acrylamide Quenching

Note. Acrylamide quenching was done on (A) L1V, (B) L1I, (C) L1L, (D) L1A, (E) L1F.
Samples contained either no lipid vesicles (Dark Blue) or (Orange ) PC, (Grey) PC:PG,
(Yellow) PE:PG, and (Light Blue) PC:Chol. All samples contained a peptide
concentration of 2 µM and lipid concentration of 250 µM for those that contained lipid
vesicles. Data is corrected for inner filter effects and are background subtracted. Data
represents an average of three replicates with SD shown by the error bars.
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Peptide Secondary Structure
While many venom peptides that act as AMPs adopt helical secondary structures,
it is also known that amino acids have differing propensities to form alpha-helical
structures. Circular dichroism (CD) spectroscopy was used to characterize the secondary
structure of the peptides in the absence and presence of lipid vesicles. The CD spectra
were recorded of the peptides in buffer or in the presence of DOPC vesicles. DOPC was
selected as 4/5 peptides appear to interact with these bilayers and the favorable
spectroscopic profile of DOPC vesicles compared to those containing PG. The CD
results are shown in Figure 5. In buffer alone, all peptides exhibited canonical spectral
signatures consistent with disordered secondary structure except L1V. When in the
presence of lipid vesicles, L1F, L1L, and L1A clearly adopt α-helical conformations
while L1I appears to have some helical character but not nearly as much as the other 3
peptides. Interestingly, there was almost no difference in CD spectra for the L1V peptide
in the presence or absence of vesicles. The L1V peptide exhibited a strong negative band
at ~204 nm which is inconsistent with disordered structures, α-helix, or β-strand [100].
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Figure 6
Circular Dichroism (CD) Spectrum

Note. Spectra of all peptide variants represented by panels (A) L1V , (B) L1I, (C) L1L,
(D) L1A, (E) L1F, each with a final concentration of 3μM. Spectra of all peptides were
collected in 10X diluted PBS represented with blue, DOPC represented by orange, and
3:1 PE:PG represented by grey. All spectra collected with lipids were done in the
presence of 200 μM lipid vesicles. All data represent the average of 64 scans with
correction of background spectra lacking peptide.
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Membrane Permeabilization
The mechanism of action of the L1 venom peptide is likely a membrane
disruptive mechanism, the effect of the hydrophobic substitutions on membrane
permeabilization was investigated using E. coli and ovine red blood cells (RBCs). The
permeabilization of the E. coli outer membrane was assayed using an enzyme-substrate
pair in which the enzyme (β-lactamase) is located in the periplasmic space while the
substrate (the chromogenic nitrocefin) is added to the exterior of cells.

Normally,

nitrocefin has limited permeability across the bilayer, but as peptides or other membrane
active agents disrupt bilayer integrity, the nitrocefin can more easily cross the outer
membrane into the periplasm where it is hydrolyzed by β-lactamase into a colored
product. A snapshot of the results after 30 minutes of exposure are shown in Figure 6A,
with full time courses shown in Figure 7. In this assay, L1L and L1F showed increased
permeability of the outer membrane, but L1F induced permeabilization more quickly and
at lower concentrations that L1L. Notably, several other peptides induced some extent of
delayed permeabilization at the highest concentrations tested, however L1I, despite the
similar biophysical behavior demonstrated earlier, exhibited no membrane disruption
above background. Similarly, the permeabilization of the E. coli inner membrane was
assessed using a cytoplasmic enzyme, β-galactosidase, and a chromogenic substrate,
ONPG. A snapshot of the results after 30 minutes of exposure are shown in Figure 6B,
with full time courses shown in Supplemental 8.

In this case, only L1L and L1F

exhibited any inner membrane permeabilizing activity, regardless of the time of peptide
exposure.
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Figure 7
Membrane Permeabilization of E. coli

Note. E. coli, (A) outer membrane and (B) inner membrane permeabilization. For both
panels L1 is shown in pink, L1V in blue, L1I in orange, L1L in grey, L1A in yellow, L1F
in black, and positive control in dark blue. All data are averages of three replicates and
SD represented by error bars. Error bars are smaller than the size of the symbols.
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Figure 8
E. coli Outer Membrane Permeabilization Assay

Note. The data sets show absorbance at 486 which indicates the periplasmic enzyme βlactamase breaking down the substrate nitrocefin. Bacteria were exposed to (A) L1, (B)
L1V, (C) L1I, (D) L1L, (E) L1A, (F) L1F, (G) Polymyxin. The legend shows the colors
that represent each concentration that starts from 15 µM and diluted down to 0.234 µM
and 0 µM being the negative control. Data represents the average and SD of 3-6 samples.
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Figure 9
E. coli Inner Membrane Permeabilization Assay

Note. These data sets show the breakdown of the ONPG substrate by the periplasmic
enzyme β-galactocidase which is represented by the absorbance at 420 nm. Varying
concentrations of (A) L1, (B) L1V, (C) L1I, (D) L1L, (E) L1A, (F) L1F, (G) CTAB. The
legend shows the colors that represent each concentration that starts from 15 µM and
diluted down to 0.234 µM and 0 µM being the negative control. Data represents the
average and SD of 3-6 samples.
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Hemolytic activity of venom peptides and, more broadly AMPS in general, has
often been a first approximation toward assessing potential for further development.
Highly hemolytic peptides are unlikely to become useful clinical therapeutics due to the
toxicity to the host. Venom peptides, often suffer from high hemolytic activity due to the
evolutionary nature of these molecules and the original purpose in the source organism.
Additionally, it has been demonstrated that the overall hydrophobicity of antimicrobial
polymers directly impacts the cytotoxic and hemolytic activity of these molecules, thus
screening these hydrophobic-substituted peptides for hemolysis is an important step. The
peptides were co-incubated with freshly isolated ovine red blood cells and peptideinduced hemolysis was determined by comparing hemoglobin leakage from treated cells
with the detergent Triton X-100 to that of untreated cells as a positive control. The
results of hemolysis assays are shown in Figure 10. The results indicate that none of the
L1 variants induced any measurable hemolysis up to 15 µM peptide. These results are
consistent with the previous results from on the L1 parent sequence and other sequence
variants of L1 [90].
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Figure 10
Hemolysis of Human Red Blood Cells (RBCs)

Note. Hemolysis of RBCs. Data sets in 10, were normalized with the experimental data
done on untreated RBCs (0% hemolysis) and RBCs treated with Triton X-100 (100%
hemolysis). For this panels L1 is shown in Pink, L1V in Blue, L1I in Orange, L1L in
Grey, L1A in Yellow, and L1F in Black. All data are averages of three replicates and SD
represented by error bars. Error bars are smaller than the size of the symbols.
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Discussion
Effects of Hydrophobic Residues
The work presented herein describes an investigation into hydrophobic amino
acids and how a uniform substitution strategy impacts the biophysical and
microbiological activity of the venom derived peptide Ponericin L1. Overall, the behavior
of the peptide can be dramatically impacted by the substitution of hydrophobic residues
in different ways, depending on the identity of the substitutions.
While many AMPs have evolved to selectively target bacterial cell membranes
over host cell membranes, the same selective pressure is not present for venom peptides.
Notably, venom peptides generally act as an offensive weapon against predators or prey
and would generally benefit from being more broad-spectrum in activity in this role
[89,101,102]. However, any hope of development of a membrane-active peptide into a
clinical therapeutic must have the ability to discriminate between host cell membranes
and bacterial cell surfaces. The biophysical results clearly show differences in affinity to
model lipid vesicles. The L1L, L1I, and L1F all show a significant change in emission
barycenter upon exposure to anionic lipid vesicles. This indicates that the peptides are
interacting with the vesicles and the Trp residue undergoes a change in local environment
into a more non-polar environment. This is consistent with the physical properties of the
peptides as these three molecules have a net positive charge and are the three most
hydrophobic peptides when evaluated using the Wimley-White hydrophobicity scale
[103]. However, the L1F is the only peptide to bind zwitterionic lipid vesicles over
similar concentration ranges and resulting in similar extent of spectral shift (~14 nm).
L1F was also the only peptide variant that showed enhanced binding to lipid composition
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PC:Chol. However, it has been seen in other published work that the aromatic structure in
phenyl alanine has a specific affinity for binding to cholesterol which is a likely cause for
the binding displayed [161]. This is also likely driven by the increased hydrophobicity of
the molecule compared to L1L and L1I. On the other hand, the L1A and L1V peptides
did not show nearly as much binding to the vesicles. While these are less hydrophobic in
general, the L1V exhibited the least shift despite being more hydrophobic than L1A.
The interaction with anionic model lipid bilayers appears to follow the same
pattern as the MIC results. The weakest binding L1A and L1V peptides showed no
antimicrobial activity at the highest concentrations tested (15µM). Conversely, L1L, L1I,
and L1F exhibited broad spectrum activity against both Gram-positive and Gramnegative strains.

Similarly, these three peptides exhibited the least quenching by

acrylamide. Taken together, the binding to bilayer surfaces and the ability to interact
with the nonpolar core of the bilayer appears to be a good screening tool for these
peptides.

Beyond this, the hydrophobic component in binding appears to have a

threshold effect on both the blue-shift of the Trp fluorescence and the antimicrobial
activity. Spectroscopically, the more hydrophobic peptides likely partition deeper into
the bilayer, burying the Trp in a more non-polar environment shield from acrylamide.
Similarly, this partitioning depth has been shown by our group and others to be a
contributor to antimicrobial activity [72,104-106]. However, the correlation of binding to
antimicrobial activity is not universal. Prior work from our group on a different peptide,
C18G-His, demonstrated that peptide exhibited a strong blue shift upon binding at neutral
pH but did not have strong antimicrobial activity at that pH regime [107]. Thus, while
this correlation between binding and activity is suggestive for L1, care must be taken to
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ensure that multiple avenues are examined when using experiments to guide design of
novel peptide antimicrobials.
An interesting result from this work is the complete lack of activity exhibited by
L1V. This was somewhat surprising due to the hydrophobic nature of the peptide
coupled with the strong cationic net charge. An examination of the data indicates that
this is likely driven by structure formation in the peptide while in solution. The L1V
peptide exhibited the highest quenching by TCE in solution as well as exhibiting the
highest degree of red-edge shift, indicative of solution interactions in the peptide. The
CD spectra show no difference in the absence or presence of lipid vesicles, supporting the
binding results that L1V does not interact with bilayers. Additionally, the CD spectra for
L1V exhibit a minimum ~205nm, somewhat red-shifted for a disordered structure and
blue-shifted for a b-strand. However, similar spectra have been reported for β-turn AMPs
by several different groups [108,109].

This formation of some β-strand structure is

consistent with valine having a lower helical propensity than the other residues examined
[110,111]. The structure prediction algorithm, iTasser, was used to generate predicted
structures of L1L and L1V which also support the formation of β-strand formation in
L1V. Although this was accurate for L1V, this did not support all structures that was
shown by the circular dichroism. This could be due the fact iTasser uses a “B-factor”
which indicates the inherent thermal mobility of the Trp residue. This is deduced by
using a threading template of proteins in combination of sequence profiles [112]. This
would not account for solvent differences and will vary in secondary structure, thus the
α-helical confirmations predicted were incorrect for the peptides in solution. Taken
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together, the data support the hypothesis that the activity of the peptides is a balance
between hydrophobicity, cationic charge, and secondary structure.

Figure 11
iTasser Structures

Note. Models presented are predictions generated through the algorithm, iTasser. The
panels (A) L1, (B) L1V, (C)L1I, (D) L1L, (E) L1A, (F) L1F represent the most likely
structure out of 5 total predicted structures for each variant.
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Finally, the lack of hemolytic activity of these peptides is striking. While not
totally unexpected based on prior results with L1-based sequences with substitutions to
the cationic residues, it is exciting that these molecules retain this beneficial property
even upon hydrophobic substitutions. Prior studies with AMP-mimetic polymers show a
clear relationship between overall hydrophobicity and cytotoxicity and/or hemolytic
activity [113,114]. In those works, the Kuroda group performed hemolysis assays on a
series of heteropolymers in which the fraction and type of hydrophobic monomers were
varied. These results clearly showed as the fraction of hydrophobic monomers increased,
or the hydrophobicity of the monomers increased (methyl vs. butyl), the hemolytic
activity also increased [113,114]. However, it appears in the L1 background that even the
most hydrophobic substitutions (L1L and L1F) do not cross the threshold for inducing
hemolytic activity. Speculatively, the strong interactions between L1F and zwitterionic
bilayers may indicate that the hemolytic threshold is not far off, as it indicates the peptide
should be able to bind to RBC or other zwitterionic mammalian membranes.
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Chapter 3
Effect of Charge and Hydrophobicity in Antimicrobial Polymethacrylates

Antimicrobial Polymers
As dicussed AMPs have promising potential as potential therapuetic agents. As
briefly mentioned in chapter 1, macromolecular approaches have also shown potential for
therapeutic agents. Polymers potential as antimicrobial agents have been discovered since
1965 and have been gaining attraction in both academic and industrial research [126]. By
2013 there were 27,845 patent issued for antimicrobial polymers. Many promising
antimicrobial polymers have been reported, and the amount of FDA-approved
antmicrobial polymers have drastically increased in the past decades [127]. Antimicrobial
polymers can have two different types of action that include either passive or active
action. Passive polymer layers that reduce protein adsorption, preventing bacterial
adhesion on their surface. Active polymers actively kill bacteria that adhere to their
surface. Interestingly enough both types of polymers rely on electrostatic interactions.
However, passive polymers have reppelling characterisitcs and do actively interact or kill
the bacteria. Active polymers can act much like AMPs and interact with cellmembranes
in disruption[126].
Polymethacrylates
Synthetic polymers have cationic, amphiphilic structures designed for membrane
disruption. However, the major draw back to synthetic polymers is that they are often
toxic to human cells or there is a lack of understanding of their toxic profiles. One of the
ways to combat this issue is to design sytnehtic polymers mimicking functional and
structural properties of less toxic host defense peptides like AMPs. Over the last decade
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new antimicrobial polymers have been developed including copolymers of β-lactams
[128], polynorbornenes [129], polymethacrylates [130,131], and polystyrenes [132,133].
Polymethacrylates are a class of materials that have a wide range of properties and many
commercial applications including: high-preformance engineering plastics, energy
storage materials, functional coatings, and biomaterials. One favorable trait of
polymethacrylates is the adjustability. The diverse range of ester groups that can be
incorporated is one reason why polymethacrylates have such varied properties [134].

Figure 12
MMA & PMMA

B

A

Note. Figure 12A and 12B were modified from a scientific article from the Encyclopedia
of Polymeric Nanomaterials [151]. (A) is methyl methacrylate (MMA) and (B) is the
poly (methyl methacrylate) (PMMA) monomer.
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Synthetic polymers have been widely used as biocides or used in combination
with other antimicrobials [152-154]. These syntheitc biocides are cationic, amphiphilic
structure that are designed to cause membrane disruption. The draw back to most of these
polymers is the inherent cytoxicity of polymers to human cells. To combat these issues
the design of these polymers were oriented around the much less toxic host-defense
peptides. These peptidomimetic polymers over the last decade have been further finely
tuned to increase favorable traits such as functionality, amphiphilic balances, polymer
sizes, antimicrobial activity, and decrease hemolytic activity [152,155-158].
Polymethacrylates can be finely tuned for antimicrobial activity and selectivity through
the modifcation of the composition of cationic and hydrophobic groups much like AMPs.
This is evident by a recent study on the role of hydrophobicity and hemolytic activty of
polymeacrylate derivatives. In the study it was elucidated for these polymethacrylate
derivatives that as hydrophobicity increased, so did antimicrobial activity and hemolytic.
Although there was a lack of selectivity that could be caused by the inherent property of
those synthetic polymers, this study gives insight that composition can dictate overall
activity [150].
Indole Polymers
In biological and biochemical structures indoles are ubiquitous with attracted
interest in multiple areas such as pharmaceuticals, fragances, agrochemicals, and dyes.
This can be attributed to tbeir unique elctrical, chemical, and optical properties [135136]. The multiple reaction sites on the indole group allow for easy tunability [137,138].
Side chain tryptohphan-substituted polymers have gained traction for their inherent
fluorescence, making it easy for tacking in biological systems and molecular imaging
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[139]. Fluorescence of proteins through the excitation of L-tryptohphan residues is well
known and a commonly practice diagnostic tool to explore their conformation [140]. It
also has been demonstrated that L-tryptophan-rich peptides play a significant role in
membrane penetration [141,142].
Due to structure and characteristics of indole polymers, they may mimic other
traditonal Trp-rich peptides. For example indole polymers may serves as good mimetics
of AMPs like indolicidin and tritrpticin. Indolicidin, a 13 residue peptide in which 5 of
them are Trp residues, is one of the shortest naturally occuring and linear AMPs. This
AMP is a fairly attractive lead molecule for it’s potency, selectivity, and wide range of
activity [147]. Tritrpticin is a member of the cathelicidin family and is another Trp-rich
(3 Trp residues), short sequenced AMP. However, tritrpticin has an extra positive charge
compared to indolicidin with four positively charged residues localized at the C- and Nterminus [148]. Interestingly enough these AMPs do have a traditonal mode of action.
Trp-rich AMPs (TrAMPs) like these cross the bacterial membrane and interact with
intercellular targets. Although these peptides have a broad range of activity, they do not
affect the integrity of the membrane.[149] For example both these peptides cross the
bacterial membrane and interact with DNA to inhibit protein synthesis, causing cell death
[147,148].
Of the many types of antimcrobial polymers that have been developed, cationic
polymers have gained the most attention. They mainly consist of cationic and
hydrophobic functional groups with mechanisms mimicking AMPs [143]. The cationic
functional groups, much like AMPs, facilitate the adsorption on to the surface of the
cellular membrane. This coupled with hydrophic properties of the L-tryptophan side
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chains could lead to increased antmicrobial activity. For example, there was a study done
on synthisized cationic star-shaped polypeptides with 3 to 8 arms evaluating their
antimicrobial activities. The study showed that increasing the amount of arms of the
polypeptide resulted in an increase of antimicrobial activity, anything passed 8 arms had
no significant increase. More imporantly for each number of arms, when the L-lysine was
modified to be an indole group, it resulted in the best antimicrobial activity. It also
exhibited improved cytotoxicity without comprimising the hemolytic activities [144].
This shows a potential in controlling the compositon of indole and cationic groups to
increase selectivity and antimicrobial activity.
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Figure 13
Polymethacrylate Structures

A

B

Note. Both figures 9A and 9B are modified figures from a publication from ACS Macro
Letters [145]. Both series of polymethacrylates were synthesized and synthesized by our
collaborators at Commonwealth Scientific and Industrial Research Organization (CSIRO)
in Melbourne Australia. Random copolymers containing Amine-Indole side chains (PAI1,PAI-2,PAI-3 (red)) as Lysine-Tryptophan mimics and Gaunidine-Indole side chains
(PGI-1, PGI-2, PGI-3 (blue)) as Arginine-Tryptophan Mimics.
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Materials and Methods
Preparation of Polymethacrylates
Random copolymer series PAI and PGI were synthesized and obtained by our
collaborators in Australia Common Wealth Scientific and Industrial Research
Organization (CSIRO). The average molecular weight for each series was calculated
using H NMR end group analysis. PAI-1, PAI-2, PAI-3 had average molecular weights of
5600, 6300, 5300 g/ mol respectively. PGI-1, PGI-2, and PGI-3 had average molecular
weights of 6000, 6500, and 5700 g/ mol respectively [145]. PAI (Amine-indole side
chain) was synthesized to mimic as Lysine-Tryptophan mimics. Each polymer has a
different mass percentage of the indole side chain, PAI-1 (31%), PAI-2 (19%), and PAI-3
(5%). PGI (Guanidine-indole side chains) was synthesized to mimic ArginineTryptophan Mimics. Each polymer has a different mass percentage of indole side chain
PGI-1 (33%), PGI-2 (19%), PGI-3 (6%). 4 mgs of polymer was weighed out and
dissolved in .5 mL of dH2O to make an 8 mg / mL stock for experiments.
Lipid Preparation
Lipids were obtained prepared in the same manner and concentrations as
previous chapter.
Binding Experiments
Binding experiments were prepared and preformed in the same manner as
previous chapter. However, a PC:Chol composition was not tested and the final polymer
concetration was .1 mg / mL in the same PBS buffer from chapter 2.
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Acrylamide Quenching
Acrylamide quenching experiments were prepared and preformed in the same
manner as chapter 2 without a PC:Chol composition and with a final polymer
concentration of .1mg / mL in the same PBS buffer as chapter 2.
10-DN Quenching
10-Doxyl nonadecane (10-DN) was purchased from Avanti Polar Lipids
(Albaster, Alabama). 10-DN stock was made by taking a single ampule and diluting it
with 1 mL of 200 proof ethanol for a final concentration of 2.7 mM. Lipid vesicles in the
same manner as acrylamide quenching with the exception of of drying down 10-DN with
lipid compositions. To do this, 10% of the final lipid concentration used in the acrylamide
protocol would be replaced with 10-DN. The following changes to lipid compositions are
as follows: 100% DOPC will be change to 90:10 (DOPC:10-DN) , for PC:PG the new
ratio will be 65:25:10 (PC:PG:10-DN), and for PE:PG the new ratio will be 6:25:10
(PE:PG:10-DN). Flourescence readings were taken at excitation: 280 nm and emisson:
340 nm.
Inner and Outer Membrane Permeabilization
Both experiments were prepared and preformed in the same manner as the
previous chapter, with the excpetion that the final concentration of Polymer started at .1
mg / mL and then serialdiluted down to .0016 mg / mL , with a negative control in the
last well.
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Hemolysis
Hemolysis was prepared and preformed in the same manner as the previous
chapter, with the excpetion that the final concentration of Polymer started at .1 mg / mL
and then serialdiluted down to .0016 mg / mL , with a negative control in the last well.
Results
Lipid interactions
The mechanism to cationic biocides are likely to mimic that of traditional
membrane disrupting AMPs. To do this the first step would be to bind to the surface of
the bacterial cell. Similarly, to chapter 2, the inherent environmental sensitivity of the
indole side chain was utilized to elucidate the membrane binding capabilities of each
polymethacrylate series. Much like the Trp residue in the previously discussed AMPs, the
indole side chain will exhibit a red shifted emission barycenter in aqueous solution, and
when bound to lipid bilayers the emission will blue shift to lower wavelengths. The
change in the emission barycenter compared to that in absence of vesicles was plotted as a
function of total lipid concentration (Figure 14). Lipid composition of vesicles was either 100%
DOPC, 3:1 DOPC:DOPG, 3:1 POPE:POPG. The results of this experiment show that there is
varied behavior between indole percentage, lipid composition, and between the two different
series (PAI & PGI). For PAI there is a larger blue shift at lower concentrations when the indole
percentage is the highest, especially for anionic lipid compositions. The PAI series exhibits that
when the indole percentage is the highest there is more significant binding at lower
concentrations, however at 350 µM of lipid vesicle the lowest indole percentage shows the
greatest shift. PGI shows similar results in the sense that when the indole percentage is 19% at
350 µM there is more binding than when the indole percentage is higher. However, at lower
concentrations when the indole percentage is 19% the binding is significantly less. Both show
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significantly larger barycenter shifts when binding PG-containing, indicating that electrostatic
forces

are

a

strong

driver

in

the

bilayer

association

of

these

peptides.

Figure 14
Binding to Lipid Vesicles

Note. Polymer binding was assayed using fluorescence by titrating SUVs into a polymer
containing sample with a final concentration of 2 μM. After each addition the spectral
barycenter was calculated and then a Δ barycenter was calculated by taking the difference
between the initial barycenter and that of each addition. Polymethacrylates that were
assayed were (A) PAI-1, (B) PGI-1, (C) PAI-2, (D) PGI-2, (E) PAI-3, and (F) PGI-3. In
all panels blue represents PC, orange 3:1 PC:PG, and grey 3:1 PE: PG. All data are
averages of 3 replicates and SD is represented by error bars.
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Figure 15
Normalized Barycenter Shifts

Note. Normalized emission spectra for PAI-1 (A), PGI-1 (B), PAI-2 (C), PGI-2 (D), PAI3 (E), and PGI-3 (F) polymers before (red) and after (blue) interacting with lipid vesicles.
Data are representative spectra after subtraction of a background spectrum. All shifts
representative of samples containing 0 µM and 350 µM lipide (PC:PG).
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To gather more information into the bilayer interactions, the same quenching
technque was used from the previous chapter were utilized. Acrylamide strongly
quenches fluorescence of Trp residues in an aqueous environmentand but does not exert
this effect if buried into the lipid bilayer. In this case, the fluorescence of the indole was
monitored for quenching by acrylamide. Stern-volmer quenching plots were created to
analyze the data and Ksv (slopes of a linear fit to the data) are shown in Table 3. The the trends
represented by the data in table 3 are consistant with the barycenter shift data from figure 14. As
stated previously the barycenter shift was greatest when the lipid compostion contained an
anionic component. The quenching assay confirms this by the reduction of quenching between
the polymer being solution (free) state and when bound to the anionic vesicles. When comparing
the interactions between zwitter ionic vesicles and anionic vesicles, there is a sigficantly smaller
KSV when bound to anionic vesicles than zwitterionic. However, an interesting result is that at
higher indole percentage for either series shows a significantly lower Ksv value. This would
mean tht the indole side chain PAI-1 and PGI could be significantly less exposed to the aqueous
environment.
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Table 4
Fluorescence Quenching

PAI-1
PAI-2
PAI-3
PGI-1
PGI-2
PGI-3

2.42
3.40
4.07
5.26
7.64
6.07

PBS
±
±
±
±
±
±

0.45
0.43
2.55
0.48
2.66
1.95

Acrylamide Quenching (( Ksv(M-1))
DOPC
PC:PG
1.07
± 0.78
1.07
±
2.33
± 0.47
1.24
±
4.59
± 0.28
4.30
±
5.27
± 0.48
3.00
±
6.97
± 0.74
4.99
±
4.27
± 0.02
4.64
±

0.78
0.15
0.82
0.35
0.25
1.57

0.81
1.57
4.24
0.36
3.05
2.57

PE:PG
±
±
±
±
±
±

0.11
0.20
0.89
0.24
0.26
0.69

Note. Abbreviations: DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine; DOPG, 1,2dioleoyl-sn-glycero-3-phospho-(1’-rac-glycerol). Data are averages of 3 replicates with
SD.
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Figure 16
Acrylamide Quenching

Note. Acrylamide quenching was performed on (A) PAI-1, (B)PGI-1, (C) PAI-2, (D)
PGI-2, (E) PAI-3, and (F) PGI-3. Samples contained either no lipid vesicles (yellow),
(blue) DOPC, (orange) PC:PG, and (grey) PE:PG. All samples contained a peptide
concentration of 2 µM and lipid concentration of 250 µM for those that contained lipid
vesicles. Data is corrected for inner filter effects, dilution, and are background subtracted.
Data represents an average of three replicates with SD shown by the error bars.
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Membrane Permeabilization
The mechanism to cationic biocides are likely to mimic that of traditional
membrane disrupting AMPs. Due to the similarities of the mode of actions the effect of
charge and hydrophobicity on membrane permeabilization can be investigated the same
as the previous chapter. A snapshot of the outer membrane permeabilization 30 minutes after
the bacterial culture was exposed to polymers is shown in Figure 13B, with full time courses
shown in figure 14. The lysine-tryptohan mimicing polymers (PAI) showed similar trends to that
of the arginine-tryptophan mimicking polymers (PGI) however, PAI induced permeabilization
more quickly. PAI-3 showed to have permeabilized the quickest between all polymer variations
One possible explaination could be that the positively charged amide in the side chain allows for
better electrostatic interactions. Interestingly enough, both series exhibited permeabilization
occurred better at lower than max concentrations of the assay. Both polymer series exhibited this
trend but it was most evident in the PGI series where smaller concentrations exhibited enhanced
permeabilization. This could be attributed to aggregation occuring that would prevent interactions
with the membrane. The PGI variants display this concept the best. The postively charged side
chain that allows for better electrostatic interactions with the surface of the membrane may
prevent aggregation, or reduce the effects aggregation may have on permeabilization. Although
these polymers permeabilize the outer membrane, the results from the inner permeabilization
assay displayed the opposite. A snap shot of the results after 30 minutes of exposure are displayed
in figure 13A and a full time course in figure 15. These results elucidate that neither polymer
series are capable of permeabilizing the inner membrane.
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Figure 17
Membrane Permeabilization of E. coli

Notes. E. coli , (A) Inner membrane and (B) outer membrane permeabilization. For both

panels PAI-1 is shown in blue, PAI-2 in orange, PAI-3 in grey, PGI-1 in yellow, PGI-2 in
black, PGI-3 in green, and positive control represented by dark blue. All data are
averages of three replicates and SD represented by error bars. Error bars are smaller than
the size of the symbols.
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Figure 18
E.coli Outer Membrane Permeabilization Assay

Note. The data sets show absorbance at 486 which indicates the periplasmic enzyme β-

lactamase breaking down the substrate nitrocefin. Bacteria were exposed to (A) PAI-1,
(B) PGI-1, (C) PAI-2, (D) PGI-2, (E) PAI-3, (F) PGI-3, (G) Polymyxin. The legend
shows the colors that represent each concentration that starts from 1 mg/mL serially
diluted down to .00156 mg/mL and 0 mg/mL being the negative control. Data represents
the average and SD of 3-6 samples.
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Figure 19
E. coli Inner Membrane Permeabilization Assay

Note. These data sets show the breakdown of the ONPG substrate by the periplasmic
enzyme β-galactocidase which is represented by the absorbance at 420 nm. Varying
concentrations of (A) PAI-1, (B) PGI-1, (C) PAI-2, (D) PGI-2, (E) PAI-3, (F) PGI-3, (G)
CTAB. The legend shows the colors that represent each concentration that starts from 1
mg/mL serially diluted down to .00156 mg/mL and 0 mg/mL being the negative control.
Data represents the average and SD of 3-6 samples.
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Hemolytic activity can be utilized in the same manner as it is for venom peptides and
other AMPs. This activity is a valid approximation in assesing the potential for further research
and development. If the hemolytic activity is too high for low concentrations than it wouldn’t be
useful to develop that compound further . One of the bigger disadvantages to using polymers as
antimcrobial agents is the cytoxicity. The hemolysis assay was preformed using the same ovine
blood (RBC) and positive control as described in chapter 2. The results of the hemolysis assay
for all polymer variants are displayed in figure 13C. These results indicate a small amount of
hemolytic activity coming from the largest concentration (0.1mg/mL). The largest precent of
hemolytic activity came from PGI-2 (9.5%) and the lower end coming from PAI-1 ( >1%).
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Figure 20
Hemolysis

Notes. Hemolysis of RBCs. Data sets were normalized with the experimental data done
on untreated RBCs (0% hemolysis) and RBCs treated with Triton X-100 (100%
hemolysis). In these panels PAI-1 is shown in blue, PAI-2 in orange, PAI-3 in grey, PGI1 in yellow, PGI-2 in black, and PGI-3 in green. Panel (A) is a smaller scale (-4% to 10
%) of panel (B) (-10% to 100%). All data are averages of three replicates and SD
represented by error bars. Error bars are smaller than the size of the symbols.
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10-DN Quenching
10-Doxyl nonadecane (10-DN) has similar quenching features as acrylamide.
However, acrylamide quenches the fluorescence of the Trp residue in aqueous solution
[159-160]. 10-DN quenches fluorescence if the Trp residue is in a non-polar environment
much like the lipid bilayer. This would suggest that the results from this quenching are
almost the reciporcal to that of acrylamide, quenching will not happen if the Trp remains
in aqueous environment. In this case, the quenching of fluorescence caused by the indole
was monitored by using this assay to investigate the penetration of the indoles into the
bilayer. The change in fluorescence intensity for each polymer variation is displayed in
figure 21. The lipid composition of vesicles were either 100% DOPC, 3:! PC:PG and 3:1
PE:PG. These results showed no trend in quenching in comparison to the results from the
acrylamide quenching assay. For example, the results from the lipid binding experiment
and acrylamide quenching assay suggest that the polymer has enhanced binding to
annionic lipid compositions. However, as clear as those results were, an assesment like
that cannot be made through these results.
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Figure 21
10-DN Quenching

Note. The following figure shows fluorescence intensity for each polymer exposed to
different lipid compositions. Blue represents DOPC, orange represents PC:PG, and grey
represents PE:PG. All data was corrected for background with and without 10-DN, SD is
represented by error bars.
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Discussion
The work presented explains the investigation into the the effects of charge and
hydrophibicity on polymethacrylate polymers. These results indicate that a balance
between hydophobicity and cationic composition effect the antimicrobial activity greatly.
When the cationic composition is higher, it leads to greater binding across a myriad of
concentrations, however when looking the PGI series that lacks the cationic side chain
only lower concentrations favored activity.
Cationic biocide polymers act in a similar fashion as AMPs where as their
cationic nature allows for electrostatic interactions with the negatively charged bacterial
membrane [146]. Sythnesized polymers can and have been used to mimick the features of
AMPs while reducing the draw backs such as manufcaturing expense, easibility of
production and chemcial alterations, and amendability in the intergration to drug delivery
systems [84]. Cationic biocide polymers must be able to preform selectively between host
cells and bacterial cell surfaces to have any further development as a potnential
therapeutic. These results show a significant difference in binding affinitiy to model lipid
vesicles. Both polymer series PAI and PGI show a significantly larger shift to binding to
anionic lipid vesicles. This is indicative of the indole side chain undergoing a change in
local environment a more non-polar one. All polymer variants caused a barycenter shift
in zwitterionic lipid vesicles but the difference between that and 100% DOPC was
drastically different. This would imply that the anionic component of those vesicles were
the primary cause for binding. PAI-1 , PAI-2, PAI-3 seemed to show a greater affinity of
binding compared to their PGI counterpart. The postively charged side chain could be
responisble for this, allowing for more electrostatic interactions.
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This can be further elucidated through the results of the acrylamide quenching
assay. This is shown by a consistently lower Ksv displayed by the PAI series.
Interestingly enough, the acrylamide quenching assay showed that for the anionic lipid
model that the more cationic variants had significantly more quenching. For example,
there is larger shift in barycenter for PAI-3 (6% indole) than PAI-1 (33% indole) but
PAI-1 showed significanlty less quenching. This could mean that although the
electrostatic interactions allowed for the initial binding to the membrane, the greater
hydrophibicity allowed for a deeper penetration into lipid bilayer. This becomes more
evident by comparing the results of PAI-3 and PGI-3, where PGI-3 had even less
quenching and more hydrophibicity. Currently, the aggregation state of the polymers as a
function of concentration is being carried out using dynamic light scattering (DLS). This
could effectively give the size of the polymethacrylate derivatives in solution. This study
could give information on the relationship of aggregation and concentration. This could
possibly show that 0.1 mg/mL is a high enough concentration to cause aggregation,
preventing any signifcant quenching by 10-DN.
Finally there is a rather small amount of hemolytic activity which isn’t totally
unexpected. Hydrophobicity has been known to directly impact the cytoxic and hemolytic
activity of polymers [110,150]. To get a better understanding of the toxic profile of these
polymers the hemolysis assay was an essential step. These results showed that as the ratio
of cationic compostion increased, the hemolytic activity was signifanctly less. This was
interesting to see considering that the lipid binding models showed binding to the zwitter
ionic indicating that polymers should be able to bind to RBC or other zwiterionic
mammalian membranes.
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Chapter 4
Conclusions
L1 Ponericin Data
The data present in this thesis displays the hydrophobic substituated variants of
the L1 peptide are membrane binding and can adopt an α-helical structure upon binding.
The identity of the hydrophobic substiuents play a significant role in the antimicrobial
acitvity of this peptide. A bulkier hydrophobic substiuent like phenylalanine had an over
all better job at binding and permeabilizing of the membrane than smaller substituents
like alanine and valine. Confirmation of the substituents could also play a role in
antimicrobial activity. For example, L1L (leucine) showed signifcantly less binding and
permemabilization than L1I (isoluecine), the substituents are isomers of each with
isoleucine having a more rigid structure. These peptide variants showed secondary
structures in zwitter ionic and anionic vesicles that could correlate to antimicrobial
activity with the exception of the L1A variant. Peptides adopting α-helical secondary
strucutres is a common feature when investigating the membrane disrupting abilities of
AMPs. However, as shown L1A forms a α-helical structure with little to no binding in
lipid models as well as antmicrobial activity. This is evidence suggesting that the degree
of hydrophobicity has a direct impact. The venom peptide L1 shows great potential as a
selective antimicrobial platform because of its low hemolytic activity and tunable
antimicrobial activity. Future studies can be done on the overall net charge, in
combination of hydrophobic/hydrophilic balance. Another useful study could be done on
using non-natural amino acids in attempts to solve problems with bioavailability while
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maintaining the antmicrobial activity profile and provide important fundemental
understandings for designing more effective and selective antimicrobial molecules.
Polymethacrylate Data
The data presented in this thesis shows that these polymethacrylate variants have
similar characteristics as traditonal membrane disrupting AMPs. This becomes more
prevalent in the lipid binding studies. The polymers bind better to anionic lipid vesicles
than zwitter ionic suggesting electrostatic interactions is a primary mode of action. The
data also suggests that there is a balance between the cationic charge and hydrophobicity
of the polymethacrylate. When the side chain was cationic, binding to lipid models as
well as antimicrobial activity was significantly higher. This balance also had an important
role in hemolytic activity. The PAI series that contained the cationic side chain showed
signifcantly less hemolytic activity regardless of the indole percentage. The increase
hydrophobicity may have also lead to aggregation resulting in higher activity at lower
concentrations of polymer. Future studies can be done to investigate the effects of the
identity of cationic groups on antimicrobial activity. Overall, this study shows
polymethacrylates as valid AMP mimetic polymer and a potential platform for a
therapuetic agent.
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